• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    US Salivary Gland Infection Market

    ID: MRFR/Pharma/17473-HCR
    100 Pages
    Garvit Vyas
    October 2025

    US Salivary Gland Infection Market Research Report By Diagnosis (Plain radiography, sialography, high-resolution ultrasonography, Computed tomography (CT), Magnetic Resonance Imaging (MRI), radionuclide scintigraphy, others, CT sialography (ultrafast technique), fluoroscopic/conventional sialography (with or without digital subtraction), MR sialography), By Treatment (medication, surgery, aspiration, home care, others, antibiotics, dicloxacillin, cephalosporins, clindamycin, others, removal of part of the parotid salivary gland, removal of a...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Salivary Gland Infection Market Infographic
    Purchase Options

    US Salivary Gland Infection Market Summary

    The US Salivary Gland Infection market is projected to grow from 1.5 USD billion in 2024 to 4 USD billion by 2035.

    Key Market Trends & Highlights

    US Salivary Gland Infection Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 9.33 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 4 USD billion, indicating robust growth potential.
    • In 2024, the market is valued at 1.5 USD billion, reflecting the current demand for treatment options.
    • Growing adoption of advanced diagnostic techniques due to increasing awareness of salivary gland infections is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.5 (USD Billion)
    2035 Market Size 4 (USD Billion)
    CAGR (2025-2035) 9.33%

    Major Players

    Merck and Co, Teva Pharmaceutical Industries, AstraZeneca, Novartis, Eli Lilly, GlaxoSmithKline, Bristol Myers Squibb, Gilead Sciences, Pfizer, Amgen, Roche, AbbVie, Sanofi, Johnson and Johnson, Bayer

    US Salivary Gland Infection Market Trends

    The US Salivary Gland Infection Market is experiencing several key trends shaped by advancements in medical practices and rising awareness among the public. One significant market driver is the increasing prevalence of salivary gland infections, often linked to viral infections, dehydration, and autoimmune diseases. With the aging population in the US, the demand for effective treatment options has risen. Innovative diagnostic tools, such as salivary diagnostic tests, are being developed, which enhance the ability to detect infections early, leading to better patient outcomes.

    There are also opportunities to be explored in the development of new therapies and treatment methods targeting the underlying causes of salivary gland infections. Increased investment in research and development by pharmaceutical and biotechnology companies, along with support from the US government, provides a promising environment for creating novel interventions. Healthcare providers are increasingly focusing on tailored solutions, such as personalized medicine and minimally invasive procedures, to address the needs of patients affected by these infections.

    Recent trends show a notable rise in public health campaigns aimed at educating individuals about the importance of oral hygiene and hydration in preventing salivary gland infections. This growing awareness may lead to increased screening and early intervention, which can help mitigate the severity of infections. Additionally, telemedicine is becoming more prevalent, allowing patients to consult healthcare professionals conveniently, thereby improving access to care. All these dynamics indicate that the US Salivary Gland Infection Market is poised for growth as stakeholders respond to emerging healthcare needs and demographic shifts.

    Market Segment Insights

    Salivary Gland Infection Market Diagnosis Insights

    The Diagnosis segment of the US Salivary Gland Infection Market plays a crucial role in the identification and management of salivary gland disorders. This segment encompasses various advanced imaging techniques that facilitate the accurate diagnosis of conditions affecting the salivary glands. Techniques such as plain radiography are fundamental for initial assessments and can provide preliminary information about the anatomy and structure of salivary glands. Sialography, on the other hand, allows for detailed visualization of the salivary duct system, making it invaluable for diagnosing obstructions, strictures, or stones.

    High-resolution ultrasonography offers a non-invasive alternative with the added advantage of providing real-time imaging, enabling the detection of lesions or inflammation effectively. 

    Computed tomography (CT) and Magnetic Resonance Imaging (MRI) are significant modalities that enhance diagnostic accuracy for complex cases by providing high-quality images that aid in evaluating salivary gland pathologies. CT scans are particularly efficient in assessing various anatomical structures in detail, while MRI excels in soft tissue characterization, making both techniques indispensable in the diagnosis process. Radionuclide scintigraphy is another valuable tool that measures the function of salivary glands, allowing practitioners to assess salivary production which is critical for comprehensive evaluations.

    Furthermore, specialized techniques such as CT sialography (ultrafast technique) and MR sialography extensively contribute to the diagnosis by enabling the visualization of the ductal system without the need for contrast medium, making them preferable in specific clinical scenarios. 

    The fluoroscopic or conventional sialography, whether with or without digital subtraction, has been a long-standing method in salivary gland diagnostics, enabling the identification of strictures or calculi within the ducts. Overall, the diverse methodologies within this Diagnosis segment reflect the rapid advancements in technology and imaging capabilities, aligned with the growing awareness of salivary gland disorders in the US healthcare setting. The rising prevalence of these infections and related disorders reinforces the demand for a comprehensive and effective diagnostic approach, driving innovation and enhancing patient outcomes in the US Salivary Gland Infection Market. 

    Salivary Gland Infection Market Treatment Insights

    The Treatment segment of the US Salivary Gland Infection Market plays a crucial role in addressing this health concern, which impacts a significant number of individuals across the nation. Various approaches within this segment are utilized, including medication options like antibiotics such as dicloxacillin, cephalosporins, and clindamycin that are essential for combating bacterial infections. Surgical interventions, specifically the removal of part or all of the parotid salivary gland, as well as the removal of the submandibular salivary gland, are pivotal for resolving severe conditions when conservative treatments fail. 

    Aspiration techniques are also employed to relieve discomfort by draining accumulated fluid. Home care practices, such as increased water intake, resting, refraining from smoking, and massaging the gland with heat, are significant for enhancing recovery and patient comfort. This diverse range of treatments addresses both immediate symptoms and long-term health outcomes, driving the demand for effective solutions within the US. With rising awareness and advancements in treatment options, the segment is well-positioned to support the growing US Salivary Gland Infection Market revenue while meeting patient needs effectively.

    The segment's evolution reflects ongoing trends toward personalized medicine and an emphasis on patient-centric care strategies.

    Salivary Gland Infection Market End User Insights

    The US Salivary Gland Infection Market showcases a diverse segmentation based on End Users, including hospitals and clinics, medical research centers, academic institutes, and others. Hospitals and clinics play a crucial role in the diagnosis and treatment of salivary gland infections, being the primary point of care for patients experiencing symptoms. Medical research centers contribute significantly to advancements in understanding these infections through innovative studies and clinical trials, thereby fostering improved treatment options. 

    Academic institutes are essential for educating healthcare professionals about the latest research and treatment methodologies. The other segment covers various healthcare settings that also contribute to patient care and research, underscoring the collaborative nature of the industry. The increasing incidence of salivary gland infections and advancements in medical technologies drives the demand across these segments, ensuring that they remain integral to the market's evolution. Furthermore, government initiatives to promote health awareness can enhance patient visits to both hospitals and clinics, thereby influencing growth trends in the US Salivary Gland Infection Market revenue.

    Get more detailed insights about US Salivary Gland Infection Market

    Key Players and Competitive Insights

    The US Salivary Gland Infection Market presents a dynamic landscape characterized by the presence of a diverse range of pharmaceutical companies competing to address the needs of patients suffering from salivary gland infections. With increasing awareness regarding oral health and related complications, the market has seen a rise in demand for effective treatment options. This has led to significant advancements in research and development, as companies strive to innovate and enhance their product offerings.

    The competitive landscape is shaped by various factors including technological advancements, shifting consumer preferences, and regulatory changes, all of which contribute to a challenging yet promising environment for market players. Strategic partnerships and collaborations are also common practices among firms aiming to fortify their market position and broaden their product portfolios.

    Key Companies in the US Salivary Gland Infection Market market include

    Industry Developments

    The US Salivary Gland Infection Market has witnessed several notable developments recently. In October 2023, Gilead Sciences announced the initiation of a new clinical study focused on innovative antiviral therapies for treating salivary gland infections, emphasizing their commitment to tackling unmet medical needs in this area. Additionally, Merck and Co. reported a significant milestone in their Research and Development efforts for a new antibiotic designed to combat bacterial infections related to the salivary glands.

    Over the last couple of years, several companies, including Teva Pharmaceutical Industries and AstraZeneca, have increased their investments in developing combined therapies, which are expected to enhance treatment outcomes. 

    In the realm of mergers and acquisitions, Novartis completed its acquisition of a biopharmaceutical firm in September 2023, which is expected to bolster its product pipeline for infections, including those affecting salivary glands. These movements indicate a robust interest and growth in the market, driven by both innovative R&D and strategic business expansions by leading companies such as Bristol Myers Squibb and Eli Lilly, enhancing their capabilities in addressing salivary gland infections effectively.

    Market Segmentation

    Salivary Gland Infection Market End User Outlook

    • hospitals & clinics
    • medical research centers
    • academic institutes
    • others

    Salivary Gland Infection Market Diagnosis Outlook

    • Plain radiography
    • sialography
    • high-resolution ultrasonography
    • Computed tomography (CT)
    • Magnetic Resonance Imaging (MRI)
    • radionuclide scintigraphy
    • others
    • CT sialography (ultrafast technique)
    • fluoroscopic/conventional sialography (with or without digital subtraction)
    • MR sialography

    Salivary Gland Infection Market Treatment Outlook

    • medication
    • surgery
    • aspiration
    • home care
    • others
    • antibiotics
    • dicloxacillin
    • cephalosporins
    • clindamycin
    • removal of part of the parotid salivary gland
    • removal of all of the parotid salivary gland
    • removal of the submandibular salivary gland
    • increased water intake
    • rest
    • refraining from smoking
    • massaging the gland with heat

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 1.21(USD Billion)
    MARKET SIZE 2024 1.5(USD Billion)
    MARKET SIZE 2035 4.0(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 9.326% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Merck and Co, Teva Pharmaceutical Industries, AstraZeneca, Novartis, Eli Lilly, GlaxoSmithKline, BristolMyers Squibb, Gilead Sciences, Pfizer, Amgen, Roche, AbbVie, Sanofi, Johnson and Johnson, Bayer
    SEGMENTS COVERED Diagnosis, Treatment, End User
    KEY MARKET OPPORTUNITIES Increased prevalence of infections, Advancements in diagnostic technologies, Growing demand for effective treatments, Rising awareness and education, Expansion of telemedicine services
    KEY MARKET DYNAMICS Rising incidence of infections, Increasing awareness and diagnosis, Advancements in treatment options, Growing geriatric population, High demand for rapid testing solutions
    COUNTRIES COVERED US

    FAQs

    What is the expected market size of the US Salivary Gland Infection Market in 2024?

    The US Salivary Gland Infection Market is expected to be valued at 1.5 billion USD in 2024.

    What will be the market size of the US Salivary Gland Infection Market by 2035?

    By 2035, the US Salivary Gland Infection Market is projected to reach a value of 4.0 billion USD.

    What is the compound annual growth rate (CAGR) for the US Salivary Gland Infection Market from 2025 to 2035?

    The US Salivary Gland Infection Market is expected to grow at a CAGR of 9.326% from 2025 to 2035.

    Which diagnosis segment holds the largest market share in 2024?

    In 2024, the sialography segment is expected to hold the largest market share, valued at 0.4 billion USD.

    How much is the Magnetic Resonance Imaging (MRI) segment expected to be valued at in 2035?

    The MRI segment of the market is anticipated to be valued at 0.7 billion USD in 2035.

    Who are the key players in the US Salivary Gland Infection Market?

    Major players in the market include Merck and Co, Teva Pharmaceutical Industries, AstraZeneca, Novartis, and Pfizer among others.

    What are the growth drivers for the US Salivary Gland Infection Market?

    Key growth drivers include increasing prevalence of salivary gland infections and advancements in diagnostic technologies.

    What opportunities exist for emerging companies in this market?

    Emerging companies can capitalize on new diagnostic methods and develop innovative treatment options for salivary gland infections.

    What challenges does the US Salivary Gland Infection Market currently face?

    Challenges include a lack of awareness regarding salivary gland infections and the availability of effective treatment options.

    What impact does regionality have on the US Salivary Gland Infection Market?

    Regionality influences market dynamics, with different regions exhibiting diverse prevalence rates and healthcare infrastructure affecting growth.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials